ALK and non-small cell lung carcinoma: Nowadays, molecular testing in advanced non-small cell lung cancer (NSCLC) patients includes screening for targetable alterations, e.g., EGFR mutations or ALK rearrangements, and, in addition, factors predictive of response to immunotherapy, thus, immune checkpoint inhibitors (ICIs).